

GENIUS PHARMA

CENIT PROJECT

The pharmaceutical companies Laboratorios Almirall SA, Laboratorios Dr. Esteve SA, Palau Pharma SA and the technology-based companies GalChimia SL, Crystax Pharmaceuticals SL and Enantia SL created the consortium GENIUS PHARMA, AIE for the development and consolidation in Spain of key technologies in the drug discovery area.

The main objective of the project is to develop, build and exploit technology platforms and best practices in the drug discovery process, covering stages ranging from identification of new therapeutic targets to the identification of candidates for preclinical development.

GENIUS PHARMA will promote new technologies among public research organisations and technology-based companies for its use by pharmaceutical companies. The project focuses its results in the areas of inflammation (with emphasis on respiratory and skin diseases), metabolic syndrome, analgesia, organ transplantation and autoimmune diseases.

In this sense, GENIUS PHARMA tries to offer to the Spanish Pharmaceutical sector additional know-how for the development of preclinical research.

More than 30 research organisations such as the Fundación Genoma España, Barcelona Scientific Park, Institut Català d'Investigació Química, University of Granada, University of Santiago de Compostela, University of Valencia, Pompeu Fabra University (IMIM)... participate in the project.

GENIUS PHARMA project is supported by the CENIT Programme (managed by CDTI), in order to create national strategic R&D consortiums, and received 47% subsidy of the global budget (period 2006 – 2009). GENIUS PHARMA is a clear example of public-private cooperation in research, development and innovation (R+D+I) in the pharmaceutical sector in Spain.

The consortium formed for the realization of this project may be the seed for the establishment of a much wider public-private network aiming to facilitate the access to the EU Seventh Framework Programme of pharmaceutical companies.